

# Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project)

STEVEN KWASI KORANG (✉ [steven.korang@ctu.dk](mailto:steven.korang@ctu.dk))

Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital <https://orcid.org/0000-0002-6521-0928>

**Sophie Juul**

Rigshospitalet

**Emil Eik Nielsen**

Rigshospitalet

**Joshua Feinberg**

Rigshospitalet

**Faiza Siddiqui**

Rigshospitalet

**Sarah Klingenberg**

Rigshospitalet

**Fanlong Bu**

Beijing University of Chinese Medicine

**Lehana Thabane**

McMaster University

**Allan Randrup Thomsen**

Kobenhavns Universitet

**Janus C Jakobsen**

Rigshospitalet

**Christian Gluud**

Rigshospitalet

---

## Protocol

**Keywords:** MEDLINE, EMBASE, CENTRAL

**DOI:** <https://doi.org/10.21203/rs.3.rs-39521/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

# Abstract

**Background:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes corona virus disease 2019 (COVID-19) which has rapidly spread worldwide. Several human randomized clinical trials assessing potential vaccines are currently underway. There is an urgent need for a living systematic review that continuously assesses the beneficial and harmful effects of all available vaccines for COVID-19.

**Methods/design:** We will conduct a living systematic review based on searches of major medical databases (e.g. MEDLINE, EMBASE, CENTRAL) and clinical trial registries from their inception onwards to identify relevant randomized clinical trials. We will update the literature search once a week to continuously assess if new evidence is available. Two review authors will independently extract data and conduct risk of bias assessments. We will include randomized clinical trials comparing any vaccine aiming to prevent COVID-19 (including but not limited to messenger RNA; DNA; non-replicating viral vector; replicating viral vector; inactivated virus; protein subunit; dendritic cell; other vaccines) with any comparator (placebo; 'active placebo'; no intervention; standard care; an 'active' intervention; another vaccine for COVID-19) for participants in all age groups.

Primary outcomes will be all-cause mortality; a diagnosis of COVID-19; and serious adverse events. Secondary outcomes will be quality of life, and non-serious adverse events. The living systematic review will include aggregate data meta-analyses, Trial Sequential Analyses, network meta-analyses, and individual patient data meta-analyses. Risk of bias will be assessed with domains, our eight-step procedure to assess if the thresholds for clinical significance are crossed, and Grading of Recommendations, Assessment, Development and Evaluations (GRADE) will assess certainty of evidence. Observational studies describing harms identified during the search for trials will also be included and analyzed separately.

**Discussion:** COVID-19 has become a pandemic with substantial mortality. A living systematic review assessing the beneficial and harmful effects of different vaccines is urgently needed. This living systematic review will regularly inform best practice in vaccine prevention and clinical research of this highly prevalent disease.

Systematic review registration: PROSPERO CRD42020196492

## Background

### Description of the condition

In 2019, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global outbreak of the respiratory illness called corona virus disease 2019 (COVID-19) (1). Since the initial outbreak in China, SARS-CoV-2 has spread globally, and COVID-19 has been labeled as the first pandemic to be caused by a coronavirus by the World Health Organization (2).

### Etiology

Coronaviruses are enveloped, positive – sense, single – stranded RNA virus genomes (3–5). The virus encodes a nonstructural replicase polyprotein and structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) (3–5). The S protein on the surface of SARS-CoV is involved in receptor recognition and the attachment to and entry into human cells. It is therefore the most common target for the development of vaccines and therapeutics (3, 5, 6).

Of the 30 coronaviruses that are known to infect mammals, birds, and other animals, seven are known to infect humans (4, 7). Four of them usually causes mild diseases such as common cold (HKU1; OC43; 229E; and NL63), whereas MERS-CoV, SARS-CoV, and now SARS-CoV-2 are prone to cause more serious diseases (5, 7).

## **Pathogenesis**

SARS-CoV is mainly transmitted from person to person through respiratory droplets (8–10). Its baseline reproduction number (the estimated number of people who will be infected with by one contagious person) is estimated at 1.87 to 3.31 (9).

The clinical presentation of COVID-19 ranges from subclinical infection with mild, self-limiting respiratory tract illness to severe progressive pneumonia, multiorgan failure, and death (11–14). Severe disease onset might result in death due to massive alveolar damage and progressive respiratory failure (12). As of June 7, 2020, there were 6.663.304 confirmed patients, 392.802 confirmed deaths, and 213 countries, areas, or territories with COVID-19 according to the World Health Organization (15). Some patients are suspected of having increased risk of severe illness (e.g. people with chronic lung disease, serious heart disease, chronic kidney disease, elderly (above 65 years), and immunocompromised people) (16).

## **How the vaccines might work**

There is currently no vaccine for COVID-19 (17). To control the growing COVID-19 pandemic, we currently rely on quarantine, isolation, and infection-control measures to prevent disease spread (18), and on supportive care including oxygen and mechanical ventilation for infected patients experiencing respiratory difficulty (19). Today, the effects of numerous vaccines against severe acute respiratory syndrome coronavirus (SARS-COV-2) are being assessed in randomized clinical trials (17) (see Table 1).

Table 1  
Summary of ongoing COVID-19 vaccine trials

No.	Name	Mechanism	Phase	Launch date	Status	Registration	Country
1	mRNA-1273	Fat-encased molecule contains mRNA that makes cells produce the S protein.	1	March 16, 2020	Recruiting	NCT04283461	USA
2 (26)	mRNA-1273	Same as above.	2	May 25, 2020	Recruiting	NCT04405076	USA
3 (91)	BNT 162	This vaccine will introduce RNA that codes for pieces of the SARS-CoV-2 virus.	1/2	April 23, 2020	Recruiting	NCT04380701	Germany
4 (92)	BNT 162	Same as No. 3.	1	April 29, 2020	Recruiting	NCT04368728	USA
5	AZD 1222	An adenovirus vector encoded with genetic information for the SARS-CoV-2 spike protein.	1/2	April 23, 2020	Not yet recruiting	NCT04324606	UK
6 (31)	AZD 1222	Same as No. 5's mechanism.	2/3	May 2020	Recruiting	NCT04400838	UK
7 (30)	Ad5-nCoV	Same as No. 5.	2	May 2020	Not yet recruiting	NCT04398147	Canada
8	Ad5-nCoV	Same as No. 5.	1	March 16, 2020	Active, not recruiting	NCT04313127	China
9	Ad5-nCoV	Same as No. 5.	2	April 12, 2020	Active, not recruiting	NCT04341389	China
10 (27)	INO-4800	This system introduces antigen-specific DNA into cells via plasmids to trigger T-cell and antibody response to the SARS-CoV-2 virus.	1	April 3, 2020	Recruiting	NCT04336410	USA

No.	Name	Mechanism	Phase	Launch date	Status	Registration	Country
11	bacTRL-Spike	Uses a genetically modified bacterium that expresses the SARS-CoV-2 spike protein to trigger an immune response.	1	April 6, 2020	Not yet recruiting;	NCT04334980	Canada
12	PRO-nCOV-1001	This vaccine will use a weakened form of the virus that causes COVID-19.	1/2	April 16, 2020	Recruiting	NCT04352608	China
13 (32)	PRO-nCOV-1002	Same as No. 12.	1/2	May 20, 2020	Not yet recruiting	NCT04383574	China
14	V-SARS	This vaccine uses orally administered tablets containing heat-inactivated SARS-CoV-2 virus.	1/2	May 15, 2020	Active, not recruiting	NCT04380532	Canada
15 (33)	PRO-nCOV-1001	Same as No. 12.	1/2	April 16, 2020	Recruiting	NCT04352608	China
16	vaccine (Vero cells)	Same as No. 12.	1/2	April 11, 2020	Inactivated	ChiCTR2000031809	China
17	vaccine (Vero cells)	Same as No. 12.	1/2	April 28, 2020	Inactivated	ChiCTR2000032459	China
18 (34)	SCB-2019	This recombinant 2019-nCoV S protein subunit-trimer vaccine relies on eliciting an immune response against the S-spike protein to prevent its docking with the host ACE2 receptor.	1	June 20, 2020	Not stated yet	NCT04405908	Australia

No.	Name	Mechanism	Phase	Launch date	Status	Registration	Country
19 (28)	NVX-CoV2373	This system introduces antigen-specific DNA into cells via plasmids to trigger T-cell and antibody response to the SARS-CoV-2 virus.	1	May 25, 2020	Recruiting	NCT04368988	Australia
20 (35)	BCG vaccine	BCG introduces weakened bacteria to trigger immune response, which may be effective against certain respiratory viruses.	4	May 26, 2020	Recruiting	NCT04414267	Greece
21	BCG vaccine	Same as No. 20.	3	April 20, 2020	Not yet recruiting	NCT04350931	Egypt
22	BCG vaccine	Same as No. 20.	4	April 20, 2020	Not yet recruiting	NCT04348370	USA
23	BCG vaccine	Same as No. 20.	3	April 2020	Not yet recruiting	NCT04362124	Columbia
24	BCG vaccine	Same as No. 20.	4	June 2020	Not yet recruiting	NCT04369794	Brazil
25	BCG vaccine	Same as No. 20.	3	March 30, 2020	Recruiting	NCT04327206	Australia
26	BCG vaccine	Same as No. 20.	3	March 25, 2020	Recruiting	NCT04328441	Netherlands
27 (36)	BCG vaccine	Same as No. 20.	3	2020-04-30	Not yet recruiting	NCT04373291	Denmark
28	BCG vaccine	Same as No. 20.	3	May 4, 2020	Recruiting	NCT04379336	South Africa
29	BCG vaccine	Same as No. 20.	3	May 2020	Not yet recruiting	NCT04384549	France
30	VPM1002 (a further development of BCG vaccine)	VPM1002 is safer and more immunogenic than the existing BCG vaccine.	3	May 18, 2020	Not yet recruiting	NCT04387409	Germany

No.	Name	Mechanism	Phase	Launch date	Status	Registration	Country
31	aAPC	This process will introduce viral proteins and immune modulatory genes to modify aAPCs and activate T-cell response.	1	February 15, 2020	Recruiting	NCT04299724	China
32	aAPC	Same as No. 31.	1/2	March 24, 2020	Recruiting	NCT04276896	China
33	AV-COVID-19	A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF.	1/2	September 2020	Not yet recruiting	NCT04386252	United States

Vaccines generally work by inducing the production of antibodies to prevent a microbial invasion (20, 21). The antibodies achieve this by either neutralizing the pathogens or assisting the immune system with opsonization and/ or phagocytosis capabilities (20, 21). Alternatively, vaccines may focus on a cell mediated/ T-cell response to develop long-term immunity (22). Animal studies suggest that vaccines inducing T-cell immune responses provide broad spectrum immunity towards coronavirus infections (23, 24). This may even make vaccines able to raise immunity towards future outbreaks of coronaviruses (23, 24).

The vaccines currently tested are based on different approaches to develop an immune response. The different vaccines use either mRNA (25, 26), DNA (27, 28), adenovirus vector (29–31), inactivated virus, weakened or killed SARS-CoV-2 (32, 33), protein subunits (34), BCG vaccines, or other vaccines (35, 36). Most vaccines attempts to train the immune system to recognize SARS-CoV-2's S protein, which the virus uses to bind to and enter host cells (3). As described above, some vaccines has more focus on inducing T cell immunity (22–24, 37).

## Why this review is important

The widespread COVID-19 paralysis of health care systems and societies worldwide is almost unprecedented. The pandemic has been a very serious burden to most health care systems and has caused serious international economic challenges. There is currently no specific way of preventing the spread of the virus besides quarantine, isolation, and infection-control measures. There is therefore a need for an efficient vaccine to adequately prevent such pandemics now and in the future.

A living systematic review of vaccines to prevent COVID-19 allows us to incorporate relevant new evidence as it becomes available, thereby decreasing the timespan from evidence to clinical practice, which is crucial in this international health crisis (38).

The development of an effective vaccine faces challenges as vaccine development takes about 10 years, and the typical success rate for upcoming vaccines is around 6% (17). Some of the new techniques such as the nucleotide-based and adenovirus-based approaches have never produced a vaccine that has been approved in the USA or the EU

before (17). More than 180 candidate vaccines have been identified as of June 10, 2020 ([https://vaccines.shinyapps.io/ncov\\_vaccine\\_landscape/](https://vaccines.shinyapps.io/ncov_vaccine_landscape/)).

We have searched in published protocols, PROSPERO, and relevant websites, and we have identified more than 3000 registered studies aiming at synthesizing COVID-19 evidence. It is currently not possible to assess the methodological quality of all these projects because most of these are only summaries of methodologies and not detailed peer-reviewed published protocols.

We identified, however, another important living review that is comparable to our present project. It is a living mapping of ongoing randomized clinical trials with network meta-analysis on all interventions for COVID-19. This review includes both prevention, including vaccines, and treatments, but does not use Trial Sequential Analysis or similar methods to handle problems with multiplicity (repeating updating of meta-analysis, multiple comparisons due to inclusion of multiple interventions, assessing multiple outcomes) (39). None of the numerous previously registered protocols take fully into account both risks of random errors (play of chance) and risks of systematic errors (bias) (40, 41).

According to a draft from the WHO, there are already more than 100 studies assessing candidates for a potential vaccine (42).

Among of these include: Moderna's mRNA COVID-19 vaccine (25), CanSino's non-replicating adenovirus type-5 (Ad5) vectored COVID-19 vaccine (43), Beijing Institute of Biological Products' Ad5-nCoV vaccine (30); Inovio Pharmaceuticals' DNA vaccine for COVID-19 (27); an inactive COVID-19 vaccines manufactured by Sinovac (33), University of Oxford's non-replicating chimpanzee adenovirus vectored vaccine ChAdOx1 nCoV-19 (31), and BioNTech's mRNA COVID-19 vaccine (44).

The present living systematic review with aggregate data meta-analyses, Trial Sequential Analyses, network meta-analyses, and individual patient data meta-analyses aims at forming the basis for evidence-based guideline recommendations for vaccines to prevent COVID-19, taking bias risk (systematic errors), play of chance (random errors), design errors, and certainty of the findings into consideration (39–41, 45–47).

## **Methods**

The protocol is reported in accordance with the reporting guideline provided in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) statement (see Additional file 1) (48, 49), and is registered in the International Prospective Register of Systematic Reviews (PROSPERO CRD42020196492) database. The review will be carried out following recommendations outlined in The Cochrane Handbook of Systematic Review of Interventions (40).

## **Criteria for considering studies for this review**

### **Types of studies**

We will search for and include randomized clinical trials, irrespective of publication status, publication year, and language. We will not search for but will include quasi-randomized studies and observational studies identified during our search for trials for the assessment of harms.

### **Types of participants**

Any participant not previously infected with SARS-CoV-2. Participants will be included irrespective of sex, comorbidities, immune status, and risk group.



# Types of interventions

## Experimental group

We will include any vaccine aiming to prevent COVID-19, i.e. all vaccines listed in Table 1 or any other vaccine irrespective of dose and duration of administration.

## Control group

We will include randomized clinical trials with any control group, i.e. head-to-head comparisons versus placebo, 'active placebo' (a matching placebo that produces noticeable adverse effects that may convince the participant being vaccinated and blinded outcome assessors that the participants are receiving an active intervention), usual care (or similar terms), no intervention, another vaccine aiming at preventing COVID-19, or any other 'active' comparator. We will accept any of these control interventions irrespective of dose and duration of administration.

Co-interventions will be allowed provided they are administered equally to the comparison groups.

## Primary outcomes

1. All-cause mortality.
2. Proportion of participants with confirmed COVID-19 (verified by RT-PCR or similar laboratory tests).
3. Proportion of participants with one or more serious adverse events. We will use the International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use—Good Clinical Practice (ICH-GCP) definition of a serious adverse event, which is any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolonging of existing hospitalization, and resulted in persistent or significant disability or jeopardized the participant (50). If the trialists do not use the ICH-GCP definition, we will include the data if the trialists use the term 'serious adverse event'. If the trialists do not use the ICH-GCP definition nor use the term serious adverse event, then we will also include the data if the event clearly fulfills the ICH-GCP definition for a serious adverse event. We will exploratorily assess each type of serious adverse event separately (see below).

## Secondary outcomes

1. Health-related quality of life (assessed on any valid continuous scale).
2. Proportion of participants with one or more adverse events not considered serious. We will exploratorily assess each type of adverse events not considered serious separately (see below).

## Exploratory outcomes

1. Proportion of participants with positive antibody response against COVID-19 antigens.
2. Individual types of serious adverse events will be analyzed separately.
3. Individual types of adverse events not considered serious will be analyzed separately.

We will use the trial results reported at maximum follow-up.

# Search methods for identification of studies

## Electronic searches

An experienced information specialist will search Cochrane Central Register of Controlled Trials (CENTRAL), Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica database (EMBASE), Latin American and Caribbean Health Sciences Literature (LILACS), Science Citation Index Expanded (SCI-EXPANDED),

Conference Proceedings Citation Index—Science (CPCI-S), Chinese Biomedical Literature Database (CBM), China Network Knowledge Information (CNKI), Chinese Science Journal Database (VIP), and Wafang Database to identify relevant trials. We will

search all databases from their inception to the present. Trials will be included irrespective of language, publication status, publication year, and publication type. For a detailed search strategy for all electronic searches, see Additional file 2.

## Searching other resources

We will identify additional references by manually searching the references of articles from the computerized databases. We will also search special COVID-19 trial sites, including a website with living mapping and living systematic review of Covid-19 studies (<https://covid-nma.com/>), a website developed by Vaccine Centre at the London School of Hygiene & Tropical Medicine ([https://vac-lshtm.shinyapps.io/ncov\\_vaccine\\_landscape/](https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/)), Lancet’s “A real-time dashboard of clinical trials for COVID-19” ([https://www.thelancet.com/journals/landig/article/PIIS2589-7500\(20\)30086-8/fulltext](https://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30086-8/fulltext)), the preprint server for health sciences, [www.medrxiv.org](http://www.medrxiv.org), and an open, accessible and frequently updated clinical trial registration for COVID-19 trials (<https://doi.org/10.12688/wellcomeopenres.15821.1>)

We will also search online trial registries such as ClinicalTrials.gov ([clinicaltrials.gov](http://clinicaltrials.gov)), the Chinese Clinical Trial Registry ([www.chictr.org.cn](http://www.chictr.org.cn)), the European Medicines Agency (EMA) ([www.ema.europa.eu/](http://www.ema.europa.eu/)), the World Health Organization (WHO) International Clinical Trials Registry Platform ([www.who.int/ictrp/](http://www.who.int/ictrp/)), and the Food and Drug Administration (FDA) ([www.fda.gov/](http://www.fda.gov/)) for ongoing or unpublished trials. We will contact experts in the field and pharmaceutical companies to enquire about additional trials. We will search for grey literature in the System for Information on Grey Literature in Europe OpenGrey ([www.opengrey.eu/](http://www.opengrey.eu/)).

## Data extraction and management

Two review authors will independently extract data from included trials in a predefined form. Disagreements will be resolved by discussion, or if required, through consultation with a third author (JCJ or CG). The two review authors will assess duplicate publications and companion papers of a trial together to evaluate all available data simultaneously (maximize data extraction, correct bias assessment). Each trial will be named after the first author and year of the primary publication, and all secondary publications will be classified under that name. We will contact the trial authors by email to specify any missing data, which may not be reported sufficiently or not at all in the publication.

## Living systematic review

A living systematic review is defined as a systematic review which is continually updated and incorporates relevant new evidence as it becomes available (51). This methodology may be particularly important in the COVID-19 pandemic, where research evidence is emerging rapidly, current evidence is uncertain, and new research may change policy or practice decisions (51).

There are four fundamental differences between conventional systematic reviews and living systematic reviews: publication format, work processes, author team management, and statistical methods (52). In this living systematic review, two independent investigators will receive an updated literature search file and include relevant newly published or unpublished trials once a week. The relevant meta-analyses, Trial Sequential Analyses, and network meta-analyses will continuously be updated, and if new evidence is available (judged by the steering committee of the LIVING

VACCINE review), the results will be published. Every month, the steering committee will discuss whether searching once a week is necessary. The living systematic review process will be initiated June 27, 2020. For an illustration of the living systematic review workflow, see Fig. 1 (with permission from Juul et al.(19) and Systematics Reviews).

## Trial characteristics

We will extract the following data: bias risk components (as defined below), trial design (parallel, factorial, crossover, cluster), number of intervention groups, length of follow-up, estimation of sample size, inclusion and exclusion criteria.

## Participant characteristics

We will extract the following data: number of randomized participants, number of participants with comorbidities and types of comorbidities, number of analyzed participants, number of participants lost to follow-up/withdrawals/crossover, age range (mean or median), and sex ratio.

## Experimental intervention characteristics

We will extract the following data: type of vaccine, type of adjuvants, dose of intervention, duration of intervention.

## Control intervention characteristics

We will extract the following data: type of control intervention, dose of intervention, duration of intervention.

## Outcomes

All outcomes listed above will be extracted from each randomized clinical trial. For each outcome, we will identify if outcomes are missing, inappropriately measured, or selectively reported according to the criteria described later in the 'missing outcome data' bias domain, the 'risk of bias in measurement of the outcome' bias domain, and the 'risk of bias in selection of the reported result' bias domain.

## Notes

We will search for information regarding industry funding of either personal or academic activities for each trial author. We will judge a publication at high risk of for-profit bias if a trial is sponsored by the industry or if just one author has affiliation to the industry. We will note in the "Characteristics of included studies" table if outcome data were not reported in a usable way. Two review authors will independently transfer data into the Stata file (53).

## Assessment of risk of bias in the included studies

Our bias risk assessment will be based on the Cochrane Risk of Bias tool—version 2 (RoB 2) as recommended in The Cochrane Handbook of Systematic Reviews of Interventions (40). We will evaluate the methodology in respect of the following bias domains:

### Bias arising from the randomization process

**Low risk of bias** Allocation was adequately concealed, AND there are no baseline imbalances across intervention groups at baseline appear to be compatible with chance, AND an adequate (random or otherwise unpredictable) method was used to generate allocation sequence, OR there is no information about the method used to generate the allocation sequence

**Some concerns** Allocation was adequately concealed, AND there is a problem with the method of sequence generation, OR baseline imbalances suggest a problem with the randomization process, OR no information is provided about concealment of allocation, AND baseline imbalances across intervention groups appear to be compatible with chance, OR no information to answer any of the signaling questions

**High risk of bias** Allocation sequence was not concealed, OR no information is provided about concealment of allocation sequence, AND baseline imbalances suggest a problem with the randomization process.

## **Bias due to deviation from intended interventions**

**Low risk of bias** Participants, carers, and personnel were unaware of intervention groups during the trial, OR participants, carers, or personnel were aware of intervention groups during the trial but any deviations from intended intervention reflected usual practice, OR participants, carers, or personnel were aware of intervention groups during the trial but any deviations from intended intervention were unlikely to impact on the outcome, AND no participants were analyzed in the wrong intervention groups (that is, on the basis of intervention actually received rather than of randomized allocation).

**Some concerns** Participants, carers, or personnel were aware of intervention groups and there is no information on whether there were deviations from usual practice that were likely to impact on the outcome and were imbalanced between intervention groups, OR some participants were analyzed in the wrong intervention groups (on the basis of intervention actually received rather than of randomized allocation) but there was little potential for a substantial impact on the estimated effect of intervention.

**High risk of bias** Participants, carers, or personnel were aware of intervention groups, and there were deviations from intended interventions that were unbalanced between the intervention groups and likely to have affected the outcome, OR some participants were analyzed in the wrong intervention groups (on the basis of intervention actually received rather than of randomized allocation), and there was potential for a substantial impact on the estimated effect of intervention.

## **Bias due to missing outcome data**

**Low risk of bias** No missing data OR non-differential missing data (similar proportion of and similar reasons for missing data in compared groups) OR evidence of robustness of effect estimate to missing data (based on adequate statistical methods for handling missing data and sensitivity analysis)

**Some concerns** An unclear degree of missing data or unclear information on proportion and reasons for missingness in compared groups AND there is no evidence that the effect estimate is robust to missing data.

**High risk of bias** A high degree of missing data AND differential missing data (different proportion of or different reasons for missing data in compared groups) AND there is no evidence that the effect estimate is robust to missing data.

## **Bias in measurement of outcomes**

**Low risk of bias** The outcome assessors were unaware of the intervention received by study participants, OR the outcome assessors were aware of the intervention received by study participants, but the assessment of the outcome was unlikely to be influenced by knowledge of the intervention received.

**Some concerns** There is no information available to determine whether the assessment of the outcome is likely to be influenced by knowledge of the intervention received.

**High risk of bias** The assessment of the outcome was likely to be influenced by knowledge of the intervention received by study participants.

## **Bias arising from selective reporting of results**

**Low risk of bias** Reported outcome data are unlikely to have been selected, on the basis of the results, from multiple outcome measurements (e.g., scales, definitions, time points) within the outcome domain, and reported outcome data are unlikely to have been selected, on the basis of the results, from multiple analyses of the data.

**Some concerns** There is insufficient information available to exclude the possibility that reported outcome data were selected, on the basis of the results, from multiple outcome measurements (e.g. scales, definitions, time points) within the outcome domain, or from multiple analyses of the data. Given that analysis intentions are often unavailable or not reported with sufficient detail, we anticipate that this will be the default judgment

for most trials.

**High risk of bias** Reported outcome data are likely to have been selected, on the basis of the results, from multiple outcome measurements (e.g., scales, definitions,

time points) within the outcome domain, or from multiple analyses of the data (or both).

## Overall assessment of risk of bias

**Low risk of bias** The trial is judged to be at low risk of bias for all domains for this result.

**High risk of bias** The trial is judged to be at high risk of bias or to be at some concerns in at least one domain for this result. Our subgroup analysis will compare the intervention effect of trials at low risk of bias with trials at high risk of bias, that is one or more domains at some concern or high risk of bias.

We will assess the domains 'missing outcome data', 'risk of bias in measurement of the outcome', and 'risk of bias in selection of the reported result' for each outcome result. Thus, we can assess the bias risk for each outcome assessed in addition to each trial. Our primary conclusions will be based on the results of our primary outcome results with overall low risk of bias. Both our primary and secondary conclusions will be presented in the Summary of Findings-tables.

## Differences between the protocol and the review

We will conduct the review according to this published protocol and report any deviations from it in the 'Differences between the protocol and the review' section of the systematic review.

## Measurement of treatment effect

**Dichotomous outcomes** We will calculate risk ratios (RRs) with 95% confidence interval (CI) for dichotomous outcomes, as well as the trial sequential analysis adjusted CIs (see below).

## Continuous outcomes

We will calculate the mean differences (MDs) and consider calculating the standardized

mean difference (SMD) with 95% CI for continuous outcomes. We will also calculate trial sequential analysis-adjusted CIs (see below).

## Dealing with missing data

We will use intention-to-treat data if provided by the trialists (54). We will, as the first option, contact all trial authors to obtain any relevant missing data (i.e. for data extraction and for assessment of risk of bias, as specified above), when individual patient data is not available.

## Dichotomous outcomes

We will not impute missing values for any outcomes in our primary analysis. In our sensitivity analyses (see paragraph below), we will impute data.

## Continuous outcomes

We will primarily analyze scores assessed at single time points. We will analyze change

from baseline scores using a MD if the same scale is used across studies. For different measurement scales in the same analysis model, we will use the SMD effect size.

In case some studies do not report change scores, but provide follow-up values, we will combine them together in a single model using MD (40). If standard deviations

(SDs) are not reported, we will calculate the SDs using relevant trial data (e.g., P values), if available. We will not use intention-to-treat data if the original report did not contain such data, per protocol data will then be used. In our best-worst worst-best scenarios (see paragraph below) for continuous outcomes, we will impute data.

## Assessment of heterogeneity

We will primarily investigate forest plots to visually assess any sign of heterogeneity. We will secondly assess the presence of statistical heterogeneity using the  $I^2$  statistic (40, 55, 56) and restricted maximum likelihood method (57, 58). We will investigate evident heterogeneity through subgroup analyses (see “Subgroup analyses and integration of heterogeneity” section below). We may ultimately decide that a meta-analysis should be avoided if heterogeneity is high (40).

## Assessment of reporting biases

We will use a funnel plot to assess reporting bias if ten or more trials are included (40). We will visually inspect funnel plots to assess the risk of bias. We are aware of the limitations of a funnel plot (i.e. a funnel plot assesses bias due to small sample size) (40). From this information, we will assess possible reporting bias. For dichotomous outcomes, we will test asymmetry with the Harbord’s test (59) if  $\tau^2$  is less than 0.1 and with the Rücker test if  $\tau^2$  is more than 0.1 (40). For continuous outcomes, we will use the regression asymmetry test (60) and the adjusted rank correlation (61).

## Unit of analysis issues

We will include randomized clinical trials for assessment of benefits and harms.

In case of trials with a cross-over design, we will include the data from the first trial period in order to avoid residual effects from the treatment (40). In order to avoid repeated observations on trial participants, we will use participant trial data at the longest follow-up (40).

We will analyze cluster randomized trials using the procedures referenced in the *Cochrane Handbook for Systematic Reviews of Interventions* (40). Where results did not control for clustering, we will contact trial authors to request an estimate of the intracluster correlation coefficient (ICC). If the trial authors are unable to provide an ICC, we will calculate the ICC using design effects (62).

If we during our searches for trials identify observational studies reporting on harms, we will tabulate these harms and report them separately in the Results section. This is to cover rare and late occurring harms. We will tabulate the types of adverse events (serious and non-serious) that are reported in the non-randomized studies retrieved with the searches

for randomized clinical trials. This will limit the information on harms in our systematic review. If benefits of certain vaccines are found, then systematic reviews of harms, based on observational studies, should be conducted (63).

## Data synthesis

All types of interventions will be included in the network meta-analysis. When analyzing individual patient data meta-analyses, aggregate data meta-analyses, and Trial Sequential Analyses, the results of each type of intervention will be analyzed separately. We will use intention-to-treat data in all analyses. We will consider using multiple imputation techniques as recommended by Jakobsen et al. (54). Please consult this publication for a detailed description of the handling of missing data. We will present best-worst and worst-best case scenarios if it is not valid to ignore missing data (41). Best-worst and worst-best case scenarios assess the potential range of impact of the missing data for the trial results.

In the 'best-worst' case scenario, it is assumed that all patients lost to follow-up in the intervention group have had a beneficial outcome, and all those with missing outcomes in the control group have had a harmful outcome (41). Conversely, in the 'worst-best' case scenario, it is assumed that all patients who were lost to follow-up in the experimental group have had a harmful outcome, and that all those lost to follow-up in the control group have had a beneficial outcome (41). When continuous outcomes are used, a "beneficial outcome" will be defined as the group mean plus two SDs of the group mean, and a "harmful outcome" will be defined as the group mean minus two SDs of the group mean (41).

## Aggregate data meta-analysis

We will undertake the meta-analyses according to the Cochrane Handbook of Systematic Reviews of Interventions (40), Keus et al. (64), and our eight-step assessment suggested by Jakobsen et al. (41). We will use the statistical software Stata version 16 (53) to analyze data. We will assess our intervention effects with both a random-effects meta-analysis (45) and fixed-effect meta-analysis for each treatment comparison separately (65). We will report the more conservative point estimate of the two (41). The more conservative point estimate is the estimate with the highest P value or the widest confidence interval. If there is substantial deviation between the random-effects and fixed-effects meta-analyses, we will report and discuss the results. We will assess a total of three primary outcomes and two secondary outcomes, and we will therefore consider a P value of 0.0167 or less as the threshold for statistical significance (41). We will investigate possible heterogeneity through subgroup analyses. We will use the eight-step procedure to assess if the thresholds for significance are crossed (41). Where multiple trial arms are reported in a single trial, we will include only the relevant arms. If two comparisons are combined in the same meta-analysis, we will halve the control group to avoid double-counting (40). Trials with a factorial design will be included. In case of, e.g. a 2 × 2 factorial designed trial, the two groups receiving COVID-19 intervention will be considered experimental groups, while the two groups receiving a placebo, 'active placebo', standard care, no intervention, or 'active' comparator will be considered control groups.

## Trial Sequential Analysis

Due to the continuous inclusion of new trials and hence repetitive testing of accumulating data when updating reviews, there is an increased risk of type I error. We wish to control the risks of both type I errors and type II errors. We will therefore perform Trial Sequential Analysis on all outcomes, in order to calculate the required information size (that is, the number of participants needed in a meta-analysis to detect or reject a certain intervention effect) and the cumulative Z-curve's breach of relevant trial sequential monitoring boundaries (46, 47, 66–72). A more detailed description of trial sequential analysis can be found in the trial sequential analysis manual (66) and at <http://www.ctu.dk/tsa/>. For dichotomous outcomes, we will estimate the required information size based on the

observed proportion of patients with an outcome in the control group (the cumulative proportion of patients with an event in the control groups relative to all patients in

the control groups), a relative risk reduction or a relative risk increase of 20% or 10%, an alpha of 1.67% for all our outcomes, a beta of 10%, and the observed diversity as suggested by the trials in the meta-analysis. For continuous outcomes, we will in the Trial Sequential Analysis use the observed standard deviation (SD), a mean difference equal

to the observed SD/2, an alpha of 1.67% for all outcomes, a beta of 10%, and the observed diversity as suggested by the trials in the meta-analysis.

## Network meta-analysis

We will obtain information about the interventions of interest either from head-to-head trials, or from trials comparing a COVID-19 intervention with placebo, standard care, no intervention, or “active placebo.” Hence, the synthesis comparator set consists of all the interventions listed in the background section as well as a placebo, ‘active placebo’, standard care, no intervention, or ‘active’ comparator trials. Each specific vaccine will be analyzed separately and will also be clustered with similar vaccines. We will describe the characteristics of the eligible randomized clinical trials and their populations using frequencies and percentages for categorical data, and means and standard deviations for continuous data.

Descriptive statistics will be also generated for each treatment comparison describing important clinical and methodological characteristics (e.g. publication year, participant age). Each outcome dataset will be presented in a different network diagram, where the size of the nodes will be proportional to the total number of randomized

participants, and the width of each edge will be weighted according to the number of studies comparing the connected treatments. We will additionally plot the edges of each network according to the average risk of bias per treatment comparison, using green for low, yellow for moderate, and red for high risk of bias. We anticipate that any participant who meets inclusion criteria is, in principle, equally likely to be randomized to any of the interventions in the synthesis comparator set. Network meta-analysis will be performed using Stata16 under frequentist framework (53) (command: `mvmeta`) (73). The network meta-analysis synthesizes evidence for the comparative effectiveness of more than two alternative interventions for the same condition (74). We will only perform network meta-analysis if a connected network of trials can be conducted.

If network meta-analysis is performed, we will, before conducting the network meta-analysis, assess two major assumptions: transitivity and consistency. We will then perform the statistical analysis in five steps. *First step* is to draw a network geometry in order to overview the network relationship. *Second step* is to assess for the transitivity assumption across treatment comparisons in the network using boxplots, as well as evaluate the assumption of consistency using the design-by-treatment interaction model as a global test (56, 74). *Third step* is to make the network forest plot or interval plot in order to illustrate the summary effect size of the comparative effectiveness among interventions. *Fourth step* is to calculate cumulative rankings for identifying a superiority among interventions. *Last step* is to evaluate publication bias or effect modifiers for a valid inference from results. Potential effect modifiers will be the same as the subgroup analyses, i.e. for-profit bias, type of comparator, age, sex, and types of vaccine. We will also explore these through network subgroup meta-analyses (see section below). The synthesized evidence through five steps would be useful to evidence-based decision-making in healthcare. Thus, network meta-analyses should be activated to guarantee the quality of health care system. The estimation of each treatment comparison will be reported separately using the relevant effect size (RR), a 95% CI, and a 95% prediction interval. Along the estimated effect sizes, we will present the ranking probabilities for each treatment being at each possible rank, as well as the surface under



the cumulative ranking curve (SUCRA) or relevant P scores (75, 76). A rank-heat plot will be used to depict the SUCRA values or P scores across all outcomes (77).

## Individual patient data meta-analysis

Results of individual patient data meta-analysis will increase the possibility to identify subgroups of patients with specific effects of the assessed interventions (78–80). If we receive individual patient data for all eligible randomized clinical trials, we will analyze the data using a one-stage analysis model based on generalized linear mixed models. This analysis will be adjusted for the categorical baseline variables that the trials used as stratifications variables in their randomization (only the common variables that all of the trials adjust for). When analyzing continuous data, we will also adjust all analyses for the baseline value.

If we are unable to obtain sufficient individual patient data, we will secondly conduct a two-stage analysis, where at 1st stage, we will reduce available individual patient data to aggregate data for each study, and at 2nd stage, we will combine all available data in a meta-analysis.

## Assessments of underlying statistical assumptions

We will systematically assess underlying statistical assumptions for all statistical analyses (53, 81, 82). In short, for all regression analyses, we will test for major interactions between each covariate and the intervention variable. We will, in turn, include each possible first order interaction between included covariates and the intervention variable. For each combination, we will test if the interaction term is significant and assess the effect size. We will only consider that there is evidence of an interaction if the interaction is statistically significant after Bonferroni adjusted thresholds (0.05 divided by number of possible interactions) and if the interaction shows a clinically significant effect. If it is concluded that the interaction is significant, we will consider both presenting an analysis separately for each (e.g. for each site if there is significant interaction between the trial intervention and 'site') and an overall analysis including the interaction term in the model (53, 81, 82). For detailed description of the planned assessments for underlying assumptions, please consult the recommendations of Nørskov et al. (53, 81, 82).

## Subgroup analyses and integration of heterogeneity

### Subgroup analyses

We will perform the following subgroup analyses when analyzing the primary outcomes (all-cause mortality, confirmed COVID-19, and serious adverse events).

1. Trials at high risk of bias compared to trials at low risk of bias. This is due to literature demonstrating overestimation of benefits and underestimation of harms in trials at risk of bias (83–85).
2. Trials without for-profit bias compared to trials at unknown or known risk of for-profit bias (37).
3. Type of vaccine (including but not limited to messenger RNA; DNA; non-replicating viral vector; replicating viral vector; inactivated virus; protein subunit; dendritic cell; other vaccines like live-attenuated, polysaccharide vaccine, conjugate vaccines).
4. Age (children and adolescents as defined by trialists; adults as defined by trialists; elderly as defined by trialists).
5. Type of antibody target (e.g., nonstructural replicase polyprotein, E protein, M protein, N-protein, S-protein or other targets)
6. Trials including participants who are immunocompromised compared to trials with participant that are not.
7. Trials including participants with history of chronic lung disease compared to trials without history of chronic lung disease.

8. Trials including unexposed participants at the time of vaccination compared to trials including participants exposed to SARS-CoV-2.
9. Trials including vaccines that target a T cell mediated response compared to trials that does not.
10. Trials at high or uncertain risks of vested interests compared to trials at low risk of vested interests. This subgroup will assess for-profit bias (37).
11. Trials using aluminium adjuvants compared to trials without aluminium adjuvants (86, 87).
12. Trials randomizing clusters compared to trials randomizing individual participants.
13. Trials using cross-over design compared to trials without cross-over design.

We will use the formal test for subgroup differences in Stata (53). We will perform any unanticipated subgroup analyses, if we identify these, as more information about this virus and its treatment becomes available.

## Sensitivity analysis

To assess the potential impact of the missing data for dichotomous outcomes, we will perform the two following sensitivity analyses on all primary and secondary dichotomous outcomes.

'Best-worst' case scenario: We will assume that all participants lost to follow-up in the experimental group survived, did not have confirmed Covid-19, had no serious adverse events, did not have serious disease, had no non-serious adverse events, and had a positive antibody response, and that all those participants lost to follow-up in the control group did not survive, had confirmed Covid-19, had a serious adverse event, had serious disease, had a non-serious adverse event, and had no a positive antibody response.

'Worst-best' case scenario: We will assume that all participants lost to follow-up in the experimental group did not survive, had confirmed Covid-19, had a serious adverse event, had serious disease had a non-serious adverse event, and had no a positive antibody response and that all those participants lost to follow-up in the control group survived, did not have confirmed Covid-19, had no serious adverse events, did not have serious disease, had no non-serious adverse events, and had a positive antibody response.

We will present results of both scenarios in our review. We will present results of both scenarios in our review.

When analyzing quality of life, a "beneficial outcome" will be the group mean plus two SDs (we will secondly use one SD in another sensitivity analysis) of the group mean, and a "harmful outcome" will be the group mean minus two SDs (we will secondly use one

SD in another sensitivity analysis) of the group mean (41). To assess the potential impact of missing SDs for continuous outcomes, we will perform the following sensitivity

analysis:

- Where SDs are missing and it is not possible to calculate them, we will impute SDs from trials with similar populations and low risk of bias. If we find no such trials, we will impute SDs from trials with a similar population. As the final option, we will impute the mean SD from all included trials.

We will present results of this scenario in our review. Other post hoc sensitivity analyses might be warranted if unexpected clinical or statistical heterogeneity is identified during the analysis of the review results (41).

## Summary of Findings table

We will create a summary of findings table including each of the prespecified outcomes (all-cause mortality, confirmed COVID-19, serious adverse events, health-related quality of life, serious disease, non-serious adverse events, and positive antibody response against COVID-19 antigens). We will use the five GRADE considerations (bias risk of the trials, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence (41, 88–90). We will assess imprecision using Trial Sequential Analysis. We will justify all decisions to downgrade the quality of evidence using footnotes, and we will make comments to aid the reader's understanding of the review where necessary. Firstly, we will present our results in the Summary of Findings table based on the results from the trials with overall low risk of bias, and secondly, we will present the results based on all trials.

## Data sharing and availability

Full syntax of all statistical analyses will be published as supplementary material. All aggregate data will be published regularly. Anonymized individual patient data will also be published if possible (we will discuss this with the trialists).

## Dissemination plan

Findings of this living systematic review will be published in international peer-reviewed scientific journals. Further, a dedicated webpage for the project will be developed, where iterative versions of the living systematic review will be accommodated with visual illustrations.

## Discussion

This living systematic review with aggregate data meta-analyses, Trial Sequential Analyses, network meta-analyses, and individual patient data meta-analyses aims at comparing the effects of all vaccines for COVID-19 versus placebo, 'active' placebo, standard care, no intervention, or an 'active' intervention. Primary outcomes will be all-cause mortality, proportion of participants with confirmed COVID-19, and serious adverse events. Secondary outcomes will be proportion of participants developing a positive antibody response to SAR-Cov2 antigens, and proportion of participants with adverse event not considered serious.

This protocol has a number of strengths. The predefined methodology is based on the Cochrane Handbook for Systematic Reviews of Interventions (40), the eight step assessment suggested by Jakobsen et al. (41), Trial Sequential Analysis (67), and GRADE assessment (89). Hence, this protocol considers both risks of random errors and risks of systematic errors. Another strength of this protocol is that we plan to do a living systematic review, which allows us to continuously surveil the literature and update the evidence-base of existing vaccinations for preventing COVID-19 regularly resulting in a decreased timespan from evidence to clinical practice. This is particularly important in this international health-care crisis. Furthermore, we plan to contact all trial authors to receive individual patient data. Often aggregate data meta-analyses and individual patient data meta-analyses tend to show similar overall results (80). However, an advantage of us including individual patient data meta-analyses is that it may allow us to study intervention effects in subgroups of participants (79).

Our protocol also has limitations. The primary limitation is the inclusion of all types of vaccines for prevention of COVID-19. This may theoretically result in a large amount of comparisons resulting in problems with multiplicity. We plan to use Trial Sequential Analysis to adjust thresholds for significance when continuously updating the review, but we do not take into account the large number of comparisons. This large risk of type 1 error will be considered when interpreting the review results.

Moreover, we primarily focus on randomized clinical trials and therefore primarily focus on benefits rather than harms as such trials are prone to miss rare and late occurring harms. When we identify observational studies reporting on

harms during our searches for trials, we will include them separately in our results. We will tabulate the types of adverse events (serious and non-serious) that are reported in the non-randomized studies retrieved only with the searches for the randomized trials. However, this will limit the information on harms in our systematic review. If benefits of certain antibiotics are found, then systematic reviews of harms, based on observational studies, should be conducted (63).

## Abbreviations

CBM: Chinese Biomedical Literature Database; CENTRAL: Cochrane Central Register of Controlled Trials; CI: Confidence interval; COVID-19: Corona Virus Disease 19; CPCI-S: Conference Proceedings Citation Index—Science; CNKI: China Network Knowledge Information; CSDR: Clinical Study Data Request; EMA: European Medicines Agency; EMBASE: Excerpta Medica database; FDA: US Food and Drug

Administration; GRADE: The Grading of Recommendations Assessment,

Development and Evaluation; ICH-GCP: International Conference on

Harmonization of technical requirements for registration of pharmaceuticals

for human use—Good Clinical Practice; MD: Mean difference; MEDLINE: Medical Literature Analysis and Retrieval System Online; MERS-CoV: Middle East Respiratory Syndrome; PRISMA: Preferred reporting items for systematic review and meta-analysis;

PRISMA-P: Preferred reporting items for systematic review and metaanalysis - protocols; PROSPERO: International Prospective Register of Systematic Reviews; RR: Risk ratio; RT-PCR: *Reverse transcription polymerase chain reaction*; SARS-CoV-2: Severe acute respiratory

syndrome coronavirus 2; SCI-EXPANDED: Science index citation expanded; VIP: Chinese Science Journal Database

## Declarations

### Acknowledgements

Not applicable.

### Authors' contributions

SKK, SJ, JCJ and CG wrote up the protocol. All authors commented on the manuscript throughout its development. All authors read and approved the final manuscript.

### Contributor information:

Steven Kwasi Korang: [steven.korang@ctu.dk](mailto:steven.korang@ctu.dk)

Sophie Juul: [sophie.juul@ctu.dk](mailto:sophie.juul@ctu.dk)

Emil Eik Nielsen: [emil.eik.nielsen@gmail.com](mailto:emil.eik.nielsen@gmail.com)

Joshua Feinberg: [wtv945@alumni.ku.dk](mailto:wtv945@alumni.ku.dk)

Faiza Siddiqui: [faiza.siddiqui@ctu.dk](mailto:faiza.siddiqui@ctu.dk)

Sarah Klingenberg: [sarah.klingenberg@ctu.dk](mailto:sarah.klingenberg@ctu.dk)

Fanlong Bu: [bufanlong@bucm.edu.cn](mailto:bufanlong@bucm.edu.cn)

Lehana Thabane: [thabanl@mcmaster.ca](mailto:thabanl@mcmaster.ca)

Allan Randrup Thomsen: [athomsen@sund.ku.dk](mailto:athomsen@sund.ku.dk)

Janus Christian Jakobsen: [janus.jakobsen@ctu.dk](mailto:janus.jakobsen@ctu.dk)

Christian Gluud: [christian.gluud@ctu.dk](mailto:christian.gluud@ctu.dk)

## **Funding**

Not applicable. This protocol did not receive any funding.

## **Availability of data and materials**

Data sharing is not applicable to this protocol article. We will publish all data including code in the supplementary material of the systematic review.

## **Ethics approval and consent to participate**

Not applicable.

## **Consent for publication**

Not applicable.

## **Competing interests**

The authors declare that they have no competing interests.

## **References**

1. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-20.
2. WHO. Novel coronavirus (2019-nCoV). Situation Report 51. Available at: [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19pdf?sfvrsn=1ba62e57\\_10](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19pdf?sfvrsn=1ba62e57_10). 2020.
3. Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. *Nat Rev Microbiol*. 2009;7(3):226-36.
4. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. *J Med Virol*. 2020;92(4):424-32.
5. Masters PS. The molecular biology of coronaviruses. *Adv Virus Res*. 2006;66:193-292.

6. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. *Proc Natl Acad Sci USA*. 2004;101(17):6641-6.
7. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33.
8. Centers for Disease Control and Prevention, Coronavirus disease 2019 (COVID-19), 2020. . 2020.
9. Ali M, Shah STH, Imran M, Khan A. The role of asymptomatic class, quarantine and isolation in the transmission of COVID-19. *J Biol Dyn*. 2020;14(1):389-408.
10. WHO. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). . World Health Organization (WHO). 2020.
11. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. *N Engl J Med*. 2020;382(19):1787-99.
12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
13. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-13.
14. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020.
15. WHO. Coronavirus disease (COVID-19) outbreak. Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. 2020.
16. Prevention CfDCa. Groups at higher risk for severe illness 2020 [
17. Mullard A. COVID-19 vaccine development pipeline gears up. *Lancet*. 2020;395(10239):1751-2.
18. Baden LR, Rubin EJ. Covid-19 - the search for effective therapy. *N Engl J Med*. 2020;382(19):1851-2.
19. Juul S, Nielsen N, Bentzer P, Veroniki AA, Thabane L, Linder A, et al. Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project). *Syst Rev*. 2020;9(1):108.
20. Pichichero ME. Booster vaccinations: can immunologic memory outpace disease pathogenesis? *Pediatrics*. 2009;124(6):1633-41.
21. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. *Clin Infect Dis*. 2008;47(3):401-9.
22. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell*. 2020;181(7):1489-501.e15.
23. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. *Antiviral Res*. 2017;137:82-92.
24. Zhao J, Zhao J, Mangalam Ashutosh K, Channappanavar R, Fett C, Meyerholz David K, et al. Airway memory CD4+ T Cells mediate protective immunity against emerging respiratory coronaviruses. *Immunity*. 2016;44(6):1379-91.
25. Diseases NIoAI. Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults. Clinical trial registration. [clinicaltrials.gov](https://clinicaltrials.gov); 2020 2020/05/28/. Report No.: NCT04283461.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj*. 1997;315(7109):629-34.
27. Safety, tolerability and immunogenicity of INO-4800 for COVID-19 in healthy volunteers - Full Text View - ClinicalTrials.gov Available at:

<https://clinicaltrials.gov/ct2/show/NCT04336410> <https://clinicaltrials.gov/ct2/show/NCT04336410?cond=NCT04336410&draw=2&rank=1> 2020.

28. Novavax. A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects. Clinical trial registration. [clinicaltrials.gov](https://clinicaltrials.gov); 2020 2020/05/26/. Report No.: NCT04368988.
29. Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, et al. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. *J Immunol.* 2008;180(2):948-56.
30. Phase I/II clinical trial of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in Canada - full text view - ClinicalTrials.gov. Available at: <https://clinicaltrials.gov/ct2/show/NCT04398147> and <https://clinicaltrials.gov/ct2/show/NCT04398147?cond=NCT04398147&draw=2&rank=1> 2020.
31. University of O. A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19. Clinical trial registration. [clinicaltrials.gov](https://clinicaltrials.gov); 2020 2020/05/22/. Report No.: NCT04400838.
32. Sinovac R, Development Co L. A randomized, double-blinded, placebo-controlled, phase I/II clinical trial, to evaluate the safety and immunogenicity of the SARS-CoV-2 inactivated vaccine (Vero Cell) in healthy population aged ≥60 Years. Clinical trial registration. [clinicaltrials.gov](https://clinicaltrials.gov); 2020 2020/05/09/. Report No.: NCT04383574.
33. Sinovac R, Development Co L. A randomized, double-blinded, placebo-controlled, phase I/II clinical trial, to evaluate the safety and immunogenicity of the SARS-CoV-2 inactivated vaccine in healthy adults aged 18~59 Years. Clinical trial registration. [clinicaltrials.gov](https://clinicaltrials.gov); 2020 2020/04/26/. Report No.: NCT04352608.
34. Clover Biopharmaceuticals AUSPL. A phase 1, randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety and immunogenicity of SCB 2019, a recombinant SARS-CoV-2 trimeric S protein subunit vaccine for COVID-19 in healthy volunteers. Clinical trial registration. [clinicaltrials.gov](https://clinicaltrials.gov); 2020 2020/05/28/. Report No.: NCT04405908.
35. Bacillus calmette-guérin vaccination to prevent COVID-19 - full text view - ClinicalTrials.gov. Available at: <https://clinicaltrials.gov/ct2/show/NCT04414267> and <https://clinicaltrials.gov/ct2/show/NCT04414267?cond=NCT04414267&draw=2&rank=1> 2020.
36. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine.* 2002;21(11):1539-58.
37. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome: systematic review with meta-analysis. *Intensive Care Med.* 2018;44(10):1603-12.
38. Garattini S, Jakobsen JC, Wetterslev J, Bertelé V, Banzi R, Rath A, et al. Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them. *Eur J Intern Med.* 2016;32:13-21.
39. Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. *BMC Med Res Methodol.* 2017;17(1):39.
40. Higgins J TJ, Chandler J, Cumpston M, Li T, Page M, et al. *Cochrane handbook for systematic reviews of interventions version 6.0* Cochrane. 2019.
41. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. *BMC Med Res Methodol.* 2014;14:120.
42. WHO. DRAFT landscape of COVID-19 candidate vaccines– 16 June 2020. <https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines>. 2020.


43. Zhu F-C, Li Y-H, Guan X-H, Hou L-H, Wang W-J, Li J-X, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *Lancet*. 2020;395(10240):1845-54.
44. Study to describe the safety, tolerability, immunogenicity, and potential efficacy of RNA vaccine candidates against COVID-19 in healthy adults - full text view - ClinicalTrials.gov. Available at: <https://clinicaltrials.gov/ct2/show/NCT04368728> and <https://clinicaltrials.gov/ct2/show/NCT04368728?cond=NCT04368728&draw=2&rank=1> 2020.
45. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. *Contemp Clin Trials*. 2015;45(Pt A):139-45.
46. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. *J Clin Epidemiol*. 2008;61(1):64-75.
47. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. *BMC Med Res Methodol*. 2009;9:86.
48. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;4:1.
49. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015;350:g7647.
50. Use ICoHoTRfRoPfH. ICH harmonised guideline: integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice (ICH-GCP). 2015.
51. Elliott JH, Synnot A, Turner T, Simmonds M, Akl EA, McDonald S, et al. Living systematic review: 1. Introduction-the why, what, when, and how. *J Clin Epidemiol*. 2017;91:23-30.
52. Elliott JH, Turner T, Clavisi O, Thomas J, Higgins JPT, Mavergames C, et al. Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap. *PLoS Med*. 2014;11(2):e1001603.
53. Auphan N, DiDonato JA, Rosette C, Helmborg A, M. K. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. *Science (New York, NY)*. 1995;270(5234):286-90.
54. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. *BMC Med Res Methodol*. 2017;17(1):162.
55. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21(11):1539-58.
56. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-60.
57. Langan D, Higgins JPT, Jackson D, Bowden J, Veroniki AA, Kontopantelis E, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. *Res Synth Methods*. 2019;10(1):83-98.
58. Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. *Res Synth Methods*. 2016;7(1):55-79.
59. Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. *Stat Med*. 2006;25(20):3443-57.
60. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629-34.
61. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. 1994;50(4):1088-101.
62. Killip S, Mahfoud Z, Pearce K. What is an intracluster correlation coefficient? Crucial concepts for primary care researchers. *Ann Fam Med*. 2004;2(3):204-8.



63. Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. *Cochrane Database Syst Rev*. 2018;5:CD012069.
64. Keus F, Wetterslev J, Gluud C, van Laarhoven CJHM. Evidence at a glance: error matrix approach for overviewing available evidence. *BMC Med Res Methodol*. 2010;10:90.
65. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. *Stat Med*. 1987;6(3):341-50.
66. Thorlund K EJ, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA). 2011.
67. CTU. TSA - trial sequential analysis. Available at: <http://www.ctudk/tsa/>. 2020.
68. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. *J Clin Epidemiol*. 2008;61(8):763-9.
69. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive—Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. *Int J Epidemiol*. 2009;38(1):287-98.
70. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. *Clin Epidemiol*. 2010;2:57-66.
71. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JPA, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? *Int J Epidemiol*. 2009;38(1):276-86.
72. Imberger G, Thorlund K, Gluud C, Wetterslev J. False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review. *BMJ Open*. 2016;6(8):e011890.
73. White IR. Network meta-analysis. *Stata J*. 2015;15(4):951–85.
74. Shim S, Yoon B-H, Shin I-S, Bae J-M. Network meta-analysis: application and practice using Stata. *Epidemiol Health*. 2017;39:e2017047.
75. Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. *BMC Med Res Methodol*. 2015;15:58.
76. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol*. 2011;64(2):163-71.
77. Veroniki AA, Straus SE, Fyraridis A, Tricco AC. The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes. *J Clin Epidemiol*. 2016;76:193-9.
78. Debray TPA, Moons KGM, van Valkenhoef G, Efthimiou O, Hummel N, Groenwold RHH, et al. Get real in individual participant data (IPD) meta-analysis: a review of the methodology. *Res Synth Methods*. 2015;6(4):293-309.
79. Schuit E, Li AH, Ioannidis JPA. How often can meta-analyses of individual-level data individualize treatment? A meta-epidemiologic study. *Int J Epidemiol*. 2019;48(2):596-608.
80. Tudur Smith C, Marcucci M, Nolan SJ, Iorio A, Sudell M, Riley R, et al. Individual participant data meta-analyses compared with meta-analyses based on aggregate data. *Cochrane Database Syst Rev*. 2016;9:MR000007.
81. Nielsen EE, Nørskov AK, Lange T, Thabane L, Wetterslev J, Beyersmann J, et al. Assessing assumptions for statistical analyses in randomised clinical trials. *BMJ Evid Based Med*. 2019;24(5):185-9.
82. Nørskov AK, Lange T, Nielsen EE, Gluud C, Winkel P, Beyersmann J, et al. Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how. *BMJ Evid Based Med*. 2020.
83. Gluud LL. Bias in clinical intervention research. *American Journal of Epidemiology*. 2006;163(6):493-501.

84. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA*. 1995;273(5):408-12.
85. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ*. 2008;336(7644):601-5.
86. Djuriscic S, Jakobsen JC, Petersen SB, Kenfelt M, Gluud C. Aluminium adjuvants used in vaccines versus placebo or no intervention. *Cochrane Database Syst Rev*. 2017;2017(9).
87. Djuriscic S, Jakobsen JC, Petersen SB, Kenfelt M, Klingenberg SL, Gluud C. Aluminium adjuvants used in vaccines. *Cochrane Database of Systematic Reviews*. 2018(7).
88. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the *Journal of Clinical Epidemiology*. *J Clin Epidemiol*. 2011;64(4):380-2.
89. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924-6.
90. Schünemann HJ, Best D, Vist G, Oxman AD, Group GW. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. *CMAJ*. 2003;169(7):677-80.
91. Biontech RNAPG. A multi-site, phase I/II, 2-part, dose-escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-2019 using different dosing regimens in healthy adults. Clinical trial registration. [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT04380701); 2020 2020/05/11/. Report No.: NCT04380701.
92. Fisher RA. On the interpretation of  $X^2$  from contingency tables, and the calculation of P. *Journal of the Royal Statistical Society*. 1922;85(1):87-94.

## Figures



**Figure 1**

Figure 1

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [PRISMAPchecklist.pdf](#)
- [SearchstrategyCovid19.pdf](#)